COVID-19大流行导致诊断延迟对英格兰癌症死亡的影响:全国人群建模研究
该全国人群建模研究利用英格兰NHS癌症登记和医院管理数据,评估COVID-19大流行期间诊断延迟对乳腺癌、结直肠癌、食管癌和肺癌患者生存的影响。通过将筛查和常规转诊路径的患者重新分配到紧急和急诊路径,模拟三种情景,估计诊断后1、3、5年的额外死亡和生命损失年。
核心结论
- 由于COVID-19大流行导致的诊断延迟,英格兰预计将出现大量可避免的癌症死亡。
- 迫切需要政策干预,特别是管理常规诊断服务的积压,以减轻对癌症患者的影响。
研究设计与样本
- 全国人群建模研究,使用英格兰NHS癌症登记和医院管理关联数据。
- 纳入2010年诊断的乳腺癌、结直肠癌和食管癌患者(随访至2014年),以及2012年诊断的肺癌患者(随访至2015年),年龄15-84岁。
- 采用诊断路径框架,模拟从2020年3月16日起12个月内诊断延迟的影响,考虑三种重新分配情景(最佳至最差)。
临床怎么用
- 需紧急管理常规诊断服务的积压,以减轻COVID-19对癌症患者的影响。
- 政策干预应优先考虑恢复筛查和常规诊断路径,减少晚期诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 pandemic, cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic cases prioritised for diagnostic intervention. In this study, we estimated the impact of delays in diagnosis on cancer survival outcomes in four major tumour types. METHODS: In this national population-based modelling study, we used linked English National Health Service (NHS) cancer registration and hospital administrative datasets for patients aged 15-84 years, diagnosed with breast, colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010, with follow-up data until Dec 31, 2014, and diagnosed with lung cancer between Jan 1, 2012, and Dec 31, 2012, with follow-up data until Dec 31, 2015. We use a routes-to-diagnosis framework to estimate the impact of diagnostic delays over a 12-month period from the commencement of physical distancing measures, on March 16, 2020, up to 1, 3, and 5 years after diagnosis. To model the subsequent impact of diagnostic delays on survival, we reallocated patients who were on screening and routine referral pathways to urgent and emergency pathways that are associated with more advanced stage of disease at diagnosis. We considered three reallocation scenarios representing the best to worst case scenarios and reflect actual changes in the diagnostic pathway being seen in the NHS, as of March 16, 2020, and estimated the impact on net survival at 1, 3, and 5 years after diagnosis to calculate the additional deaths that can be attributed to cancer, and the total years of life lost (YLLs) compared with pre-pandemic data. FINDINGS: We collected data for 32 583 patients with breast cancer, 24 975 with colorectal cancer, 6744 with oesophageal cancer, and 29 305 with lung cancer. Across the three different scenarios, compared with pre-pandemic figures, we estimate a 7·9-9·6% increase in the number of deaths due to breast cancer up to year 5 after diagnosis, corresponding to between 281 (95% CI 266-295) and 344 (329-358) additional deaths. For colorectal cancer, we estimate 1445 (1392-1591) to 1563 (1534-1592) additional deaths, a 15·3-16·6% increase; for lung cancer, 1235 (1220-1254) to 1372 (1343-1401) additional deaths, a 4·8-5·3% increase; and for oesophageal cancer, 330 (324-335) to 342 (336-348) additional deaths, 5·8-6·0% increase up to 5 years after diagnosis. For these four tumour types, these data correspond with 3291-3621 additional deaths across the scenarios within 5 years. The total additional YLLs across these cancers is estimated to be 59 204-63 229 years. INTERPRETATION: Substantial increases in the number of avoidable cancer deaths in England are to be expected as a result of diagnostic delays due to the COVID-19 pandemic in the UK. Urgent policy interventions are necessary, particularly the need to manage the backlog within routine diagnostic services to mitigate the expected impact of the COVID-19 pandemic on patients with cancer. FUNDING: UK Research and Innovation Economic and Social Research Council.
引用
- Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020. PMID: 32702310. doi:10.1016/S1470-2045(20)30388-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。